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with acellular scaffolds and others were left untreated. After 3 months,
the repair tissue of the three experimental groups was macroscopically
analyzed and processed for histological and biochemical analysis.
Results: The histologic ICRS II scale showed a statistically signiﬁcant
difference between the three experimental groups only in the param-
eters regarding the cell morphology and the surface/superﬁcial
assessment: the lesion treated with the unseeded osteochondral scaf-
folds showed higher values in chondrocytes morphology and in the
superﬁcial layer recovery, with respect to the lesions treated with the
seeded scaffolds or left untreated. The biochemical analysis showed a
higher DNA content in the lesion repaired with cellular scaffold and a
higher GAGs/DNA ratio in the lesions with a spontaneous repair
Conclusions: This osteochondral scaffold was able to repair an osteo-
chondral lesion in an in vivo model, showing a good integration with
the surrounding tissue. The quality of the repair was higher when the
scaffold was not seeded with chondrocytes, but ﬁlled with cells
migrated from subchondral bone. This tissue engineered osteochondral
composite could represent a valuable model for further in vivo studies
on the repair of chondral/osteochondral lesion.
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ENHANCED INTEGRATION WITH TREATMENT OF SPRIFERMIN
(rhFGF18) IN A CARTILAGE INJURY-REPAIR MODEL
G.R. Dodge y, A.J. Farran y, R. Cocca y, G. Meloni y, B. Mohanraj y,
A. Gigout z, R.L. Mauck y. yUniv. of Pennsylvania, Philadelphia, PA, USA;
zMerck KGaA, Darmstadt, Germany
Purpose: Osteochondral autograft transplantation (OAT) is a common
procedure for the treatment of focal articular defects. Multiple factors
likely inﬂuence the effectiveness of this procedure, including the source
of donor cartilage, health of cartilage surrounding the defect site, and
ultimately the degree to which integration occurs at the interface with
native tissue. In animal models and in vitro experiments it has been
shown that Sprifermin (recombinant human FGF18, rhFGF18) promotes
chondrocyte proliferation and extra-cellular matrix (ECM) biosynthesis,
and stimulates cartilage repair. Since in many instances OAT procedures
result in poor integration (due to low cellularity and ﬁbrous tissue
formation at the interface), we tested the hypothesis that addition of
Sprifermin would increase cartilage-to-cartilage integration by
increasing cell proliferation and ECM accumulation at the interface. We
tested this hypothesis in an in vitro cartilage explant injury model and
evaluated outcomes using mechanical, histological, and micro-com-
puted tomography (mCT) assays of the interface.
Methods: Fresh hyaline cartilage was harvested from the trochlear
groove of juvenile bovine knees (3-6 months old). Cylindrical explants
(8mm, Fig 1A) were removed with a biopsy punch and cultured over-
night in complete medium. Samples were trimmed of bone and defects
(4mm diameter) were created to form a core and annulus repair con-
struct (Fig 1B). Both the inner core and outer annulus were cultured
separately for 24 hours before the defect was ﬁlled with the original
core.
Figure 1. Preparation of cartilage-defect repair model: (A) 8mm cartilage
plug, (B) central 4mm defect creation, (C) insertion of cartilage into defect,
and (D) long term culture of repair construct.
Samples were then cultured in complete medium, or treated with
Sprifermin (rhFGF18, 100 ng/ml). Treatments consisted of one dose of
rhFGF18 for 24 hours, applied once aweek (and repeated weekly) (1þ6)
or one 24 hour treatment followed by 1 month of culture in complete
medium (1þ30 days). Samples were harvested after 4 weeks of culture.
Integration strength was evaluated through push-out mechanical
testing using an Instron 5848 and a custom testing rig (Fig 2E). For 3D
visualization, samples were soaked in a modiﬁed Lugol’s solution for 24
hours and scanned by mCT. Scans were analyzed and reconstructed
using the manufacturer’s software, and cross sections were used to
evaluate defect integration. Additional samples were ﬁxed overnight in
4% PFA and analyzed histologically for cell and matrix deposition at the
interface.Figure 2. (A-C) Transverse cross sections of 3D mCT reconstruction with
different treatments. (D) Integration strength of the repaired defect
showing increasing strength from the control to the 1þ30 treatment to
the 1þ6 treatment. (E) Experimental setup of the push-out testing rig.
Error bars are SEM.
Results: The integration strength (Fig 2D) of control samples was the
lowest (5.0 2.9 kPa), with progressively increasing properties with the
1þ30 (10.0  4.7 kPa) and 1þ6 (20.4  7.3 kPa) treatments. While the
results are striking when comparing controls and treated groups, with
the replicate numbers possible in this study, statistical signiﬁcance was
not achieved.
mCT analysis of control constructs (Fig 3, top left) showed a distinct dark
circle, indicating separation between the outer annulus and inner core,
and thus poor integration. The 1þ30 treatment (Fig 3, middle left)
showed a less distinct circle, suggesting a smaller gap and greater inte-
gration, and the 1þ6 treatment (Fig 3, bottom left) showed very homo-
genous mCTsignal across the interface, indicative of the greatest degree of
integration. Evidence of this increased integrationwas apparent on both
vertical and transverse cross sections throughout the samples.
Figure 3. mCT scans of cartilage-to-cartilage repair constructs. Left: single
mCT scan slice representative of the sample. Center: three dimensional
reconstruction. Right: cross-section of the reconstruction. The mCT scans
demonstrate increasing integration from control to 1þ30 to 1þ6
treatments.
Figure 1. Stress strain diagram of Fibrin gel (left) and the injectable plaster
(right). The ﬁbrin gel does not show any up build of forces and is poorly
adhering to the defect surface. This in contrast to the injectable plaster.
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S151Conclusions: Our results show that a transient (24 hour) exposure of
cartilage-to-cartilage repair models to Sprifermin improves integration
strength and matrix deposition at the interface (as evidenced by con-
trast-enhanced mCT showing a more uniform attenuation by increase in
GAG-containing proteoglycans). In this study, one 24 hour admin-
istrationweekly for 4 weeks leads to an overall better outcome than one
24 hour treatment over one month. This study represents for the ﬁrst
time a biologic (and in particular an FGF) has improved the integration
of cartilage surfaces in a clinically relevant repair model. The ﬁndings
implicates Sprifermin potential usefulness in surgical procedures such
as OATS and in tissue engineering approaches where cartilage like
biomaterials will be required to successfully integrate with native car-
tilage in order to achieve clinical success.
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CHONDROGENESIS FROM HUMAN INDUCED PLURIPOTENT STEM
CELLS: EPIGENETIC CAUSES OF LOW HYPERTROPHY INDUCTION
S. Park, J.-Y. Ko, G.-I. Im. Dongguk Univ. Ilsan Hosp., Goyang, REPUBLIC OF
KOREA
Purpose: The purpose of this studywas to test the in vitro chondrogenic
potential and in vivo capacity for cartilage regeneration of human iPS
(hiPS) cells.
Methods: Cell culture and differentiation of EB We used the hiPSC line
(SBI, cat# SC802A-1) generated by direct delivery of four proteins fused
to a cell penetrating peptide. hiPSCs were passaged to Matrigel-coated
polystyrene plates and cultured in the deﬁned mTeSR1 medium. To
inducemesenchymal differentiation, embryoid bodies were formed and
cultured in suspension for 11 days with hESC growth medium in low-
attachment culture dishes.
Chondrogenic differentiation: Chondrocytic differentiation was
induced by trypsinizing EB to a single cell suspension, diluting cells to a
ﬁnal concentration of 5x105 cells/ml and forming micromass pellets by
centrifugation. Micromass pellets were cultured in 15-ml conical tubes
for 21 days using DMEM/F12 medium,of supplemented with 1% ITS
(insulin-transferrin-selenium), 10-7 M dexamethasone, 50 mM ascor-
bate-2-phosphate, 50 mM L-proline, 1 mM sodium pyruvate and 10ng/
ml TGF-b3.
Analysis for chondrogenic differentiation: After 21 days of in vitro
culture, pellets were analyzed for DNA contents, GAG amount, the
expression of chondrogenic markers, and the methylation status.
Transplantation:The hiPS-pellets or alginate-hiPSCs constructs were
implanted in the osteochondral defect model rat. The rats received daily
injections of cyclosporin A to suppress immune responses in rats. After
6 weeks, the rats were sacriﬁced.
Results: Mesodermal markers increased in EB while undifferentiated ES
markersdisappeared.After 21days of chondrogenic culture inmicromass
pellets, GAG analysis showed that proteoglycan production was sig-
niﬁcantly greater in chondrogenic pellets than in undifferentiated hiPSCs
and EBs. Safranin-O staining demonstrated that the cells in chondrogenic
pellets took on the appearance of immature chondrocytes and secreted
extracellular matrix. The chondrogenic marker gene and protein
expression increased after 21days of pellet culture. The chondrogenic
pellets derived from hiPSCs have very low expression of hypertrophic or
osteogenicmarkers. Also,methylationwas increased in hiPSCs compared
to hBMSCs in the COL10A1promoter. This result suggested the epigenetic
disparity is the cause of the difference in hypertrophy.
When hiPSCs in either pellet state or in alginate hydrogel were
implanted in the osteochondral defects created on the patellar groove of
immunosuppressed rats, the defects implanted with chondro-induced
hiPSCs showed a signiﬁcantly better quality of cartilage repair than the
control defects.
Conclusions: In conclusion, this study provides a proof-of-principle
strategy for using hiPSCs as a cell source for cartilage tissue engineering.
While successful in vitro induction of chondrogenesis with improved
biochemical characteristics were obtained from hiPS cells, the working
mechanisms in the implantation of hiPS cells and strategies for further
improvement of in vivo cartilage repair with hiPS cells should be
investigated in future studies.
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INJECTABLE HYDROGELS FOR CARTILAGE REPAIR
S. Both, R. Wang, P. Dijkstra, M. Karperien. Univ. of Twente, Enschede,
NetherlandsPurpose: To create an injectable hydrogel that can be used to
plaster eroded cartilage surfaces and / or to ﬁll up focal cartilage
defects in a minimally invasive arthroscopic procedure. The plaster
should protect the damaged cartilage surface against further car-
tilage erosion and possess an optimized environment for cartilage
regeneration.
Methods: Over the last years we have develop an injectable plaster by
introducing hydroxyphenyl groups in the backbone of naturally
occurring polymers such as dextran, hyaluronic acid and heparin
which resemble or normally reside in the extracellular cartilage
matrix. This renders an injectable hydrogel which gelates in an
enzymatic peroxidase mediated reaction initiated by non-toxic con-
centrations of H2O2.
From in vitro testing we know that our plaster is biocompatible and that
it supports cartilage formation of incorporated primary chondrocytes,
mesenchymal stromal cells or combinations of both. To further improve
our injectable plaster we have introduced several cell attracting, carti-
lage-mimicking and/or chondrogenesis stimulating elements and
studied cartilage formation. The adhesive properties of the injectable
plaster was compared to clinically used ﬁbrin glue in a customized set
up. Finally pilot studies were performed in fresh horse cadavers to test
whether the plaster could be applied in focal cartilage defects in an
arthroscopic procedure. The repaired joint wasmanually ﬂexed to study
the plaster’s resistance to force.
Results: The incorporation of heparin, hyaluronic acid and chon-
droitin sulphate in a dextran based hydrogel resulted in a che-
moattractant plaster facilitating ingrowth of chondrocytes and
mesenchymal stromal cells. When chondrocytes were incorporated
the addition of these elements potently stimulated neocartilage
formation by encapsulated chondrocytes based on histological
analysis and gene expression of typical cartilage markers like
COL2A, SOX9 and AGC. The binding of the hydrogel to surface of
the defect is important for future clinical applications. Therefore
we compared our hydrogel to clinically used ﬁbrin gel and found
that gel ﬁxation of the injectable plaster is at least 1 order of
magnitude stronger than the gluing properties of ﬁbrin gel (Fig-
ure 1). In addition, rheology showed that the injectable plaster has
improved mechanical properties compared to ﬁbrin gel. Next we
tested our injectable plaster in a minimally invasive surgical pro-
cedure. Thus the gel was injected via arthroscopic procedure in a
full thickness defect in the joint of a horse. Subsequent the knee of
the horse was ﬂexed manually to test the injectable plaster which
remained in its place (Figure 2). Since this was a success we are
currently planning our next in vivo study in which the horses will
be followed in time to see how the plaster reacts in a full load
bearing joint.
Conclusions: We have developed an injectable hydrogel that gelates in
situ using a biocompatible enzymatic cross linking reaction and we
have shown that this hydrogel is chemoattractant for chondrocyte
progenitors and mesenchymal stem cells. We found that gel ﬁxation of
the injectable plaster is stronger than the gluing properties of clinically
used ﬁbrin gel. Next we demonstrated that this hydrogel can be applied
in a minimally invasive arthroscopic procedure in a horse knee and
strongly binds to cartilage and subchondral bone by covalent bonding of
the hydrogel to the native tissue.
We are nowperforming experiments in live animals to test the potential
of these injectable plasters to facilitate regeneration of damaged carti-
lage surfaces.
